COMPARE THE EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH OTHER ORAL HYPOGLYCEMIC AGENTS IN TYPE 2 DIABETES MELLITUS PATIENTSAbstract
Background: The incidence of Diabetes Mellitus has increased dramatically in recent decades. Di Peptidyl Peptidase 4 inhibitors (DPP-4) have their role in glycemic control. An impaired ‘incretin effect’, occurs in patients with type 2 Diabetes Mellitus in response to glucose intake. Objectives: The main objective of the study is to compare therapeutic outcomes and adverse drug reactions among commonly prescribed anti diabetic drug combinations in adults with type 2 diabetes mellitus. Methodology: A retrospective and prospective study experimental study was carried out for a period of one year at care diabetes centre. Results: FBS and PLBS were found to be significantly lower in DPP group when compared with SU and TZ. Adverse events such as itching, abdominal pain, constipation and weight loss are more in DPP when compared with other groups. Data from this study indicated that DPP-4 inhibitors are superior to sulfonylureas (SU) and thiazolidinediones (TZ) when used in combination with metformin (B) in glycemic control. Conclusion: DPP inhibitors provide an effective therapeutic option for individuals with Type 2 Diabetes along with obesity.